{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:56:52Z","timestamp":1790733412615,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T00:00:00Z","timestamp":1673913600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejca.2023.01.002","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T11:30:08Z","timestamp":1673091008000},"page":"77-86","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I\u2013IIA cutaneous melanoma"],"prefix":"10.1016","volume":"182","author":[{"given":"Stefanie","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9693-3221","authenticated-orcid":false,"given":"Lorenz","family":"Buser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Haferkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Berneburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Maisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Klinkhammer-Schalke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Pauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8530-780X","authenticated-orcid":false,"given":"Claus","family":"Garbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2023.01.002_bib1","first-page":"472","article-title":"Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.01.002_bib2","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1245\/s10434-019-07369-w","article-title":"Recurrence of melanoma after a negative sentinel node biopsy: predictors and impact of recurrence site on survival","volume":"26","author":"Thomas","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib3","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.1200\/JCO.22.00202","article-title":"Prognosis of patients with primary melanoma Stage I and II according to American Joint Committee on Cancer Version 8 validated in two independent cohorts: implications for adjuvant treatment","volume":"40","author":"Garbe","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib4","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (1 mm) than from thick melanomas (>4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.01.002_bib5","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992-2013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.ejca.2023.01.002_bib6","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1245\/s10434-016-5566-8","article-title":"Nodular histologic subtype and ulceration are tumor factors associated with high risk of recurrence in sentinel node-negative melanoma patients","volume":"24","author":"Faut","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib7","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejso.2018.08.031","article-title":"Sentinel node for malignant melanoma: an observational study of a consecutive single centre experience","volume":"45","author":"Belgrano","year":"2019","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.2217\/mmt.15.19","article-title":"Analysis of melanoma recurrence following a negative sentinel lymph node biopsy","volume":"2","author":"Hodges","year":"2015","journal-title":"Melanoma Manag"},{"key":"10.1016\/j.ejca.2023.01.002_bib9","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.ejso.2016.03.038","article-title":"Worse outcome for patients with recurrent melanoma after negative sentinel lymph biopsy as compared to sentinel-positive patients","volume":"42","author":"Gambichler","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib10","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/1203475417720201","article-title":"Metastatic melanoma in sentinel node-negative patients: the Ottawa experience","volume":"22","author":"Ward","year":"2018","journal-title":"J Cutan Med Surg"},{"key":"10.1016\/j.ejca.2023.01.002_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13174431","article-title":"Primary melanoma characteristics of metastatic disease: a nationwide cancer registry study","volume":"13","author":"Zhou","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.01.002_bib12","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1016\/j.surg.2015.12.002","article-title":"Prognostic factors in melanoma patients with tumor-negative sentinel lymph nodes","volume":"159","author":"Egger","year":"2016","journal-title":"Surgery"},{"key":"10.1016\/j.ejca.2023.01.002_bib13","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1002\/cam4.2358","article-title":"Survival analysis and sentinel lymph node status in thin cutaneous melanoma: a multicenter observational study","volume":"8","author":"Tejera-Vaquerizo","year":"2019","journal-title":"Cancer Med"},{"key":"10.1016\/j.ejca.2023.01.002_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djp038","article-title":"Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis","volume":"101","author":"Gould Rothberg","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.01.002_bib15","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/978-1-62703-727-3_13","article-title":"Construction and analysis of multiparameter prognostic models for melanoma outcome","volume":"1102","author":"Rothberg","year":"2014","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ejca.2023.01.002_bib16","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1002\/cncr.29634","article-title":"Revisiting determinants of prognosis in cutaneous melanoma","volume":"121","author":"Weiss","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.01.002_bib17","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3832","article-title":"Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence","volume":"101","author":"Ertekin","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.ejca.2023.01.002_bib18","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/jid.2010.149","article-title":"Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma","volume":"130","author":"Gould Rothberg","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.ejca.2023.01.002_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038222","article-title":"A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts","volume":"7","author":"Meyer","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2023.01.002_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13122902","article-title":"Identifying high-risk tumors within AJCC Stage IB-III melanomas using a seven-marker immunohistochemical signature","volume":"13","author":"Reschke","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejca.2023.01.002_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/sj.bjc.6602678","article-title":"REporting recommendations for tumour MARKer prognostic studies (REMARK)","volume":"93","author":"McShane","year":"2005","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2023.01.002_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001216","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration","volume":"9","author":"Altman","year":"2012","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2023.01.002_bib23","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/jnci\/djp335","article-title":"Use of archived specimens in evaluation of prognostic and predictive biomarkers","volume":"101","author":"Simon","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2023.01.002_bib24","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/cncr.32585","article-title":"Considering adjuvant therapy for stage II melanoma","volume":"126","author":"Poklepovic","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2023.01.002_bib25","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.2217\/fon-2019-0666","article-title":"KEYNOTE-716: phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma","volume":"16","author":"Luke","year":"2020","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib26","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2023.01.002_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejca.2019.06.011","article-title":"Impact of American Joint Committee on Cancer 8th edition classification on staging and survival of patients with melanoma","volume":"119","author":"Kanaki","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2023.01.002_bib28","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/jso.26214","article-title":"Recurrence patterns in patients with Stage II melanoma: the evolving role of routine imaging for surveillance","volume":"122","author":"Bleicher","year":"2020","journal-title":"J Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib29","first-page":"66370","article-title":"American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine","author":"Kattan","year":"2016","journal-title":"CA A Cancer J Clin"},{"key":"10.1016\/j.ejca.2023.01.002_bib30","doi-asserted-by":"crossref","first-page":"2871","DOI":"10.1245\/s10434-021-11231-3","article-title":"The impact of surveillance imaging frequency on the detection of distant disease for patients with resected stage III melanoma","volume":"29","author":"Dieng","year":"2022","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib31","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1245\/s10434-020-08407-8","article-title":"Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence","volume":"27","author":"Ibrahim","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib32","first-page":"21520","article-title":"Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy","author":"Garbe","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2023.01.002_bib33","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1186\/s12885-020-07632-4","article-title":"TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma","volume":"20","author":"Naeser","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2023.01.002_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14041040","article-title":"Quality of life in the first year of follow-up in a randomized multicenter trial assessing the role of imaging after radical surgery of stage IIB-C and III cutaneous melanoma (TRIM Study)","volume":"14","author":"Naeser","year":"2022","journal-title":"Cancers (Basel)"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804923000084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:39:28Z","timestamp":1760733568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804923000084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":34,"alternative-id":["S0959804923000084"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.002","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of high-risk patients with a seven-biomarker prognostic signature for adjuvant treatment trial recruitment in American Joint Committee on Cancer v8 stage I\u2013IIA cutaneous melanoma","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2023.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}